Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

Authors: Angela M. Minassian, Sarah E. Silk, Jordan R. Barrett, Carolyn M. Nielsen, Kazutoyo Miura, Ababacar Diouf, Carolin Loos, Jonathan K. Fallon, Ashlin R. Michell, Michael White, Nick J. Edwards, Ian Poulton, Celia Mitton, Ruth Payne, Michael Marks, Hector Maxwell-Scott, Antonio Querol-Rubiera, Karen Bisnauthsing, Rahul Batra, Tatiana Ogrina, Nathan J. Brendish, Yrene Themistocleous, Thomas A. Rawlinson, Katherine J. Ellis, Doris Quinkert, Megan Baker, Raquel Lopez Ramon, Fernando Ramos Lopez, Lea Barfod, Pedro M. Folegatti, Daniel Silman, Mehreen Datoo, Iona J. Taylor, Jing Jin, David Pulido, Alexander D. Douglas, Willem A. de Jongh, Robert Smith, Eleanor Berrie, Amy R. Noe, Carter L. Diggs, Lorraine Soisson, Rebecca Ashfield, Saul N. Faust, Anna L. Goodman, Alison M. Lawrie, Fay L. Nugent, Galit Alter, Carole A. Long, Simon J. Draper - Med 2021 cited by 167

BACKGROUND: . METHODS: adjuvant. We assessed safety, immunogenicity, and efficacy against blood-stage CHMI. Trial registered at ClinicalTrials.gov, NCT02927145. FINDINGS: reduction of the parasite growth rate and also identify other antibody feature sets by systems serology, including the plasma anti-RH5 IgA1 response, that are associated with challenge outcome. CONCLUSIONS: Our data provide a new framework to guide rational design and delivery of next-generation vaccines to protect against malaria disease. FUNDING: This study was supported by USAID, UK MRC, Wellcome Trust, NIAID, and the NIHR Oxford-BRC.